Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Kenneth Kelley
AddedMar 31, 2024
UpdatedMay 31, 2026
Kenneth Kelley

Kenneth Kelley

Board Member, SeromYx Systems

CrunchbaseLinkedIn

Kenneth Kelley's Career

SeromYx Systems
SeromYx Systems

Cambridge, MA, US

Board Member· Board
Meissa Vaccines
Meissa Vaccines

San Francisco, CA, US

Board Member· Board
PaxVax
PaxVax

Redwood City, CA, US

Co-Founder

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Kenneth Kelley's Career

SeromYx Systems
SeromYx Systems
Seed$3.1M152019Cambridge, MA, US
Board Member· Board

Leadership at SeromYx Systems

Piers WhiteheadPiers WhiteheadCEO
Galit AlterGalit AlterFounder
Meissa Vaccines
Meissa Vaccines
Series A$33.4M402014San Francisco, CA, US
Board Member· Board

Leadership at Meissa Vaccines

Lawrence BlattLawrence BlattBoard Member
William DalyWilliam DalyBoard Member
Marty MooreMarty MooreCo-Founder
Roderick TangRoderick TangCo-Founder
Michael WatsonMichael WatsonBoard Member
PaxVax
PaxVax
Private Equity$234.6M3752006Redwood City, CA, US
Co-Founder

Leadership at PaxVax

Daniel HendersonDaniel HendersonCo-Founder
Rennie CoitRennie CoitBoard Member

Similar to PaxVax

PathovaxPathovaxBaltimore, MD, USBiotechnology, Vaccinesest. 2014PathovaxBaltimore, MD, US · est. 2014

PathoVax, a Johns Hopkins biotech start-up, specializes in commercializing RGVax in bioscience.

Seed · $6M15
VaxartVaxartSouth San Francisco, CA, USOral Vaccinesest. 2004VaxartSouth San Francisco, CA, US · est. 2004

San Francisco-based biotech innovating vaccines for infectious diseases.

Public · $98.7M164
X-Vax TechnologyX-Vax TechnologyJupiter, FL, USVaccinesest. 2015X-Vax TechnologyJupiter, FL, US · est. 2015

X-Vax: A biotech firm specializing in developing vaccines for mucosal infection pathogens.

Series A · $56M39
InvVaxInvVaxLos Angeles, CA, USVaccinesest. 2012InvVaxLos Angeles, CA, US · est. 2012

InvVax, Inc.: A California-based pharmaceutical company specializing in global pandemic prevention vaccines.

Angel · $255.9k5

Kenneth Kelley's Similar Executives & Operators

WILL WEI CHENGWILL WEI CHENGBoard Member · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailJaeHong ChoiJaeHong ChoiBoard Member · KakaoKim Beom-sooKim Beom-sooCo-Founder · KakaoMason YeoMason YeoBoard Member · KakaoBrian KimBrian KimCo-Founder · KakaoSean JohSean JohBoard Member · Kakao

People Similar to Kenneth Kelley

Jeff PollockJeff PollockFounder · MB Growth PartnersRaj KrishnanRaj KrishnanCo-Founder · Biological DynamicsLea HachigianLea HachigianCo-Founder · ImmuneIDJohn BoyceJohn BoyceFounder · TigerGeneRonald ChwangRonald ChwangBoard Member · KaldooraDavid SteinbergDavid SteinbergBoard Member · Rectify Pharmaceuticals